Phoenix Financial’s ADMA Biologics ADMA Stock Holding History

Phoenix Financial’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-34,034	Closed	-$144K	–	197
2019 Q3	$144K	Buy	+34,034	New	+$142K	0.01%	184

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

Phoenix Financial's ADMA Position: Q4 2019 in Review

Phoenix Financial sold out of ADMA Biologics (ADMA) in Q4 2019, closing a stake of 34,034 shares — an estimated $144K sold.

Phoenix Financial first reported a position in ADMA in Q3 2019 and held it in 1 quarter. The position peaked at $144K in Q3 2019. 74 funds tracked by Wall St. Rank hold ADMA as of Q4 2019.

Phoenix Financial reported no remaining ADMA Biologics position as of Q4 2019 after selling out during the quarter.
Phoenix Financial sold 34,034 ADMA Biologics shares in Q4 2019, an estimated $144K.
Phoenix Financial first reported a position in ADMA Biologics in Q3 2019 and held it in 1 quarter.
Phoenix Financial's ADMA Biologics position peaked at $144K in Q3 2019.
74 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2019.

Based on Phoenix Financial's 13F filing for Q4 2019, filed 18 Feb 2020.